MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
155 hedge funds and large institutions have $2.39B invested in MyoKardia, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 74 increasing their positions, 32 reducing their positions, and 26 closing their positions.
131% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 32
1% less capital invested
Capital invested by funds: $2.41B → $2.39B (-$14.7M)
8% less funds holding
Funds holding: 169 → 155 (-14)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
42% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 26
55% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $3.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$61.6M |
| 2 |
BlackRock
New York
|
+$28.1M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$18.3M |
| 4 |
Primecap Management
Pasadena,
California
|
+$13.1M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$24.9M |
| 2 |
HM
HealthCor Management
New York
|
-$18.5M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$13.4M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$13.1M |
| 5 |
LM
Luminus Management
Houston,
Texas
|
-$6.76M |
MYOK Hedge Fund Activity: Q2 2019 in Review
155 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q2 2019, worth a combined $2.39B — down 0.61% from $2.41B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of MYOK and 15 opened new positions — a net loss of 11 holders — while 32 trimmed existing stakes and 74 added.
The largest buyer was Bellevue Group, opening a new position worth an estimated $61.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $24.9M sold.
- 155 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q2 2019, down from 169 in Q1 2019.
- Funds reported $2.39B of MyoKardia, Inc. Common Stock stock for Q2 2019, down 0.61% quarter-over-quarter.
- 15 funds opened new MyoKardia, Inc. Common Stock positions in Q2 2019 and 26 closed out, a net change of -11 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q2 2019 was Bellevue Group, an estimated $61.6M added.
- The largest MyoKardia, Inc. Common Stock seller in Q2 2019 was EcoR1 Capital, an estimated $24.9M sold.
Based on aggregated 13F filings for Q2 2019.